A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US. Tarsus Pharmaceuticals' Xdemvy (lotilaner ...
Investors in Tarsus Pharmaceuticals Inc (Symbol: TARS) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback